When Actavis took a new medical treatment to market, Eli Lilly thought it looked familiar. They had their own product that had been patented and the one from Actavis was only a slight variation. In this episode we explore the issues that arose surrounding intellectual property law and consider the wider implications when it comes to tightening or loosening the European patent system.

Music from bensound.com